INVOKANA ® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: November 2019Source: Artificial Intelligence in Medicine, Volume 101Author(s): Dunja Vrbaški, Milan Vrbaški, Aleksandar Kupusinac, Darko Ivanović, Edita Stokić, Dragan Ivetić, Ksenija DoroslovačkiAbstractMetabolic Syndrome (MetS) is associated with the risk of developing chronic disease (atherosclerotic cardiovascular disease, type 2 diabetes, cancers and chronic kidney disease) and has an important role in early prevention. Previous research showed that an artificial neural network (ANN) is a suitable tool for algorithmic MetS diagnostics, that includes solely non-invasive, low-cost and...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
The most clinically relevant new aspects of the 2019 version of the ESC Guidelines compared with the previous version published in 2013 relate to:Reclassification of cardiovascular (CV) risk.Individualized blood pressure (BP) targets.New lipid targets relating to severity of CV risk.Recommendations for the use of PCSK9 inhibitors in lipid management.New recommendations regarding the role of aspirin and the novel oral anticoagulants (NOACs) in diabetes.New recommendations for the duration of dual antiplatelet therapy post-ACS in diabetes mellitus (DM).The interpretation of the CV outcome trials in diabetes therapies and the...
Source: European Heart Journal - Category: Cardiology Source Type: research
Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agent worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields. However, lactic acidosis (LA) persists as a serious adverse effect. LA incidence is low and is not necessarily determined by the administration of metformin. Unfortunately, the concern for this complication has negatively affected the drug use, particularly in chronic kidney disease, which may impair drug excretion, and in congestive heart failure and chr...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Authors: Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL Abstract Lipopolysaccharide (LPS), a potent endotoxin present in the outer membrane of Gram-negative bacteria, causes chronic immune responses associated with inflammation. In the present study, the association between LPS and the dysbiosis of Gram-negative bacteria in the gut microbiome was determined in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (T2DM-CKD; stages 4 and 5, not on dialysis) compared with healthy individuals. Microbiome diversity was analyzed in patients with T2DM-CKD and healthy controls by sequenci...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
The sodium-dependent glucose co-transporter (SGLT-2) inhibitors are the newest class of oral agents in the armoury of the physician to combat type 2 diabetes mellitus (T2DM). The significant reduction in cardiovascular outcomes with all three SGLT2- inhibitors is now well documented (1-3), as is the reduction in chronic kidney disease (CKD) outcomes with canagliflozin (4). The effect of another SGLT-2 inhibitor, dapagliflozin, on long term CKD outcomes is the subject of a secondary analysis of the Dapagliflozin Effect on Cardiovascular Events –Thrombolysis In Myocardial Infarction 58 (DECLARE-TIMI 58) trial, recently...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Nephrology Digest Source Type: research
Purpose of review Through its direct adverse effects on the kidney and via associated intermediate disease states like type 2 diabetes and hypertension, obese has arguably become the master risk factor for chronic kidney disease (CKD). The purpose of this review is to critically evaluate bariatric surgery, which is the most effective weight reduction strategy available, as a renoprotective strategy. Recent findings Recent randomized studies confirm that bariatric surgery is effective at improving or even remitting major CKD risk factors such as type 2 diabetes and hypertension. In addition, observational studies perfo...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: DIAGNOSTICS AND TECHNIQUES: Edited by Maarten W. Taal Source Type: research
Abstract Background and Objectives: Diabetes mellitus (DM) and hypertension (HT) are characterized by cell damage caused by inflammatory and metabolic mechanisms induced by alteration in reduction-oxidative status. Serum advanced oxidation protein products (AOPP) are new markers of protein damage induced by oxidative stress. We evaluated serum levels of AOPP in a cohort of patients with DM and HT, with or without renal complications, compared with a control healthy population. Materials and Methods: The study group comprised of 62 patients with type 2 DM and 56 with HT. The 62 patients affected by DM were further ...
Source: Medicina (Kaunas) - Category: Universities & Medical Training Authors: Tags: Medicina (Kaunas) Source Type: research
The objective of this review is to show an overview to know the main UT produced in end-stage renal disease patients, and how prebiotics and probiotics intervention acts as a helpful tool in CKD treatment.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
AbstractDiabetes-related complications including cardiovascular disease, heart failure (HF), chronic kidney disease, retinopathy, and neuropathy are associated with a high burden of disease. Early initiation of glucose-lowering therapy in patients with type 2 diabetes to achieve glycemic control is important for reduction of not only microvascular risk but also of CV (cardiovascular) risk. Clinical studies have indicated that early achievement of glycemic targets is likely to have the greatest effect on preventing microvascular and macrovascular complications. In addition to improvements in glycemic control and CV risk fac...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Pharmaceuticals | Urology & Nephrology